Plant Name: Iris domestica
Taxonomic Information:
Plant ID: NPO7528
Plant Latin Name: Iris domestica
Taxonomy Genus: Iris
Taxonomy Family: Iridaceae
Plant External Links:
NCBI TaxonomyDB:
58944
Plant-of-the-World-Online:
n.a.
Used in Medicines:
Country/Region:
South Africa; Philippines; Indonesia; India; Vietnam; ThailandTraditional Medicine System:
Indian FolkGeographical Distribution:
South Africa; Philippines; Indonesia; India; Vietnam; Thailand
Geographical Distribution
See the Plant Occurrence Worldwide with Latitude and Longitude Available
Collective Molecular Activities of the Plant
List of Human Proteins Collectively Targeted by the Plant
Click Gene ID to Access Activity Profile of Individual Target
| TDP1; PIK3CB; PIK3CA; NQO2; | |
| CA14; CA12; CA9; | |
| ESR1; | |
| PTGS2; |
List of Human Cytochrome P450 Enzymes Affected by the Plant
Click Gene ID to Access Activity Profile of Individual Enzyme
Detailed Information of Target Proteins
| Protein Class | Gene ID | Protein Name | Uniprot ID | Target ChEMBL ID |
|---|---|---|---|---|
| Cytochrome P450 family 1 | CYP1A2 | Cytochrome P450 1A2 | P05177 | CHEMBL3356 |
| Cytochrome P450 family 3 | CYP3A4 | Cytochrome P450 3A4 | P08684 | CHEMBL340 |
| Enzyme_unclassified | TDP1 | Tyrosyl-DNA phosphodiesterase 1 | Q9NUW8 | CHEMBL1075138 |
| Enzyme_unclassified | PIK3CB | PI3-kinase p110-beta subunit | P42338 | CHEMBL3145 |
| Enzyme_unclassified | PIK3CA | PI3-kinase p110-alpha subunit | P42336 | CHEMBL4005 |
| Enzyme_unclassified | NQO2 | Quinone reductase 2 | P16083 | CHEMBL3959 |
| Lyase | CA14 | Carbonic anhydrase XIV | Q9ULX7 | CHEMBL3510 |
| Lyase | CA12 | Carbonic anhydrase XII | O43570 | CHEMBL3242 |
| Lyase | CA9 | Carbonic anhydrase IX | Q16790 | CHEMBL3594 |
| Nuclear hormone receptor subfamily 3 group A | ESR1 | Estrogen receptor alpha | P03372 | CHEMBL206 |
| Oxidoreductase | PTGS2 | Cyclooxygenase-2 | P35354 | CHEMBL230 |
Enrichment of Gene Ontology of Target Proteins (Activity≤1μM)
Detailed Information of Enriched Gene Ontolgy
| GO Type | GO Category | Enriched GO Terms | p-Value | Adjusted p-Value | Enriched Genes |
|---|---|---|---|---|---|
| MF | GO:0003824; catalytic activity | GO:0004089; carbonate dehydratase activity | 6.228E-08 | 1.356E-03 | CA12, CA14, CA9 |
| BP | GO:0051179; localization | GO:0015701; bicarbonate transport | 1.797E-06 | 9.780E-03 | CA12, CA14, CA9 |
| MF | GO:0003824; catalytic activity | GO:0034875; caffeine oxidase activity | 1.768E-06 | 9.780E-03 | CYP1A2, CYP3A4 |
Enriched KEGG Pathways of Target Proteins (Activity≤1μM)
Top 10 KEGG Pathways (ordered by adjusted p-value)
Detailed Information of Enriched KEGG Pathways
| Pathway Category Top Level | Pathway Category Second Level | Pathway ID | Pathway Name | p-Value | Adjusted p-Value | Enriched Genes |
|---|---|---|---|---|---|---|
| 09100 Metabolism | 09102 Energy metabolism | hsa00910 | Nitrogen metabolism | 6.026E-31 | 8.377E-29 | CA12, CA1, CA3, CA5B, CA2, CA5A, CA4, CA7, CA6, CA9, CA14, CA13 |
| 09160 Human Diseases | 09161 Cancers | hsa05230 | Central carbon metabolism in cancer | 1.690E-09 | 1.175E-07 | PKM, PIK3CA, PIK3CB, TP53, HIF1A, EGFR |
| 09150 Organismal Systems | 09156 Nervous system | hsa04726 | Serotonergic synapse | 3.831E-08 | 1.775E-06 | CYP2C9, APP, MAOA, CYP2C19, PTGS2, PTGS1 |
| 09100 Metabolism | 09111 Xenobiotics biodegradation and metabolism | hsa00982 | Drug metabolism - cytochrome P450 | 1.263E-07 | 4.391E-06 | CYP2C9, MAOA, CYP1A2, CYP3A4, CYP2C19 |
| 09160 Human Diseases | 09161 Cancers | hsa05205 | Proteoglycans in cancer | 1.290E-06 | 2.561E-05 | PIK3CA, PIK3CB, TP53, HIF1A, ESR1, EGFR |
| 09160 Human Diseases | 09161 Cancers | hsa05204 | Chemical carcinogenesis | 3.018E-07 | 6.992E-06 | CYP2C9, CYP1A2, CYP3A4, CYP2C19, PTGS2 |
| 09100 Metabolism | 09103 Lipid metabolism | hsa00591 | Linoleic acid metabolism | 1.809E-07 | 5.029E-06 | CYP2C9, CYP1A2, CYP3A4, CYP2C19 |
| 09150 Organismal Systems | 09152 Endocrine system | hsa04919 | Thyroid hormone signaling pathway | 1.850E-06 | 3.095E-05 | PIK3CA, PIK3CB, TP53, ESR1, HIF1A |
| 09160 Human Diseases | 09161 Cancers | hsa05213 | Endometrial cancer | 2.004E-06 | 3.095E-05 | PIK3CA, PIK3CB, TP53, EGFR |
| 09160 Human Diseases | 09161 Cancers | hsa05223 | Non-small cell lung cancer | 2.705E-06 | 3.418E-05 | PIK3CA, PIK3CB, TP53, EGFR |
| 09150 Organismal Systems | 09152 Endocrine system | hsa04923 | Regulation of lipolysis in adipocytes | 2.705E-06 | 3.418E-05 | PIK3CA, PIK3CB, PTGS2, PTGS1 |
| 09160 Human Diseases | 09161 Cancers | hsa05214 | Glioma | 4.931E-06 | 5.206E-05 | PIK3CA, PIK3CB, TP53, EGFR |
| 09100 Metabolism | 09103 Lipid metabolism | hsa00590 | Arachidonic acid metabolism | 4.078E-06 | 4.724E-05 | CYP2C9, CYP2C19, PTGS2, PTGS1 |
| 09160 Human Diseases | 09161 Cancers | hsa05212 | Pancreatic cancer | 5.243E-06 | 5.206E-05 | PIK3CA, PIK3CB, TP53, EGFR |
| 09160 Human Diseases | 09161 Cancers | hsa05218 | Melanoma | 7.025E-06 | 6.510E-05 | PIK3CA, PIK3CB, TP53, EGFR |
| 09160 Human Diseases | 09161 Cancers | hsa05215 | Prostate cancer | 1.726E-05 | 1.411E-04 | PIK3CA, PIK3CB, TP53, EGFR |
| 09160 Human Diseases | 09161 Cancers | hsa05222 | Small cell lung cancer | 1.507E-05 | 1.309E-04 | PIK3CA, PIK3CB, PTGS2, TP53 |
| 09150 Organismal Systems | 09152 Endocrine system | hsa04915 | Estrogen signaling pathway | 2.629E-05 | 2.030E-04 | PIK3CA, PIK3CB, ESR1, EGFR |
| 09160 Human Diseases | 09161 Cancers | hsa05200 | Pathways in cancer | 5.873E-05 | 3.710E-04 | PIK3CA, PIK3CB, PTGS2, HIF1A, TP53, EGFR |
| 09160 Human Diseases | 09161 Cancers | hsa05231 | Choline metabolism in cancer | 2.844E-05 | 2.081E-04 | PIK3CA, PIK3CB, HIF1A, EGFR |
| 09130 Environmental Information Processing | 09132 Signal transduction | hsa04066 | HIF-1 signaling pathway | 3.072E-05 | 2.135E-04 | PIK3CA, PIK3CB, HIF1A, EGFR |
| 09140 Cellular Processes | 09143 Cell growth and death | hsa04210 | Apoptosis | 1.017E-04 | 5.657E-04 | PIK3CA, LMNA, PIK3CB, TP53 |
| 09130 Environmental Information Processing | 09132 Signal transduction | hsa04071 | Sphingolipid signaling pathway | 5.589E-05 | 3.699E-04 | OPRD1, PIK3CA, PIK3CB, TP53 |
| 09160 Human Diseases | 09167 Infectious diseases | hsa05160 | Hepatitis C | 8.340E-05 | 4.830E-04 | PIK3CA, PIK3CB, TP53, EGFR |
| 09150 Organismal Systems | 09152 Endocrine system | hsa04921 | Oxytocin signaling pathway | 1.622E-04 | 8.182E-04 | PIK3CA, PIK3CB, PTGS2, EGFR |
| 09130 Environmental Information Processing | 09132 Signal transduction | hsa04150 | mTOR signaling pathway | 1.569E-04 | 8.182E-04 | PIK3CA, PIK3CB, HIF1A |
| 09160 Human Diseases | 09166 Endocrine and metabolic diseases | hsa04930 | Type II diabetes mellitus | 8.045E-05 | 4.830E-04 | PKM, PIK3CA, PIK3CB |
| 09160 Human Diseases | 09161 Cancers | hsa05203 | Viral carcinogenesis | 4.376E-04 | 1.738E-03 | PKM, PIK3CA, PIK3CB, TP53 |
| 09130 Environmental Information Processing | 09132 Signal transduction | hsa04370 | VEGF signaling pathway | 1.648E-04 | 8.182E-04 | PIK3CA, PIK3CB, PTGS2 |
| 09160 Human Diseases | 09161 Cancers | hsa05210 | Colorectal cancer | 1.730E-04 | 8.292E-04 | PIK3CA, PIK3CB, TP53 |
| 09150 Organismal Systems | 09152 Endocrine system | hsa04917 | Prolactin signaling pathway | 2.695E-04 | 1.148E-03 | PIK3CA, PIK3CB, ESR1 |
| 09160 Human Diseases | 09161 Cancers | hsa05220 | Chronic myeloid leukemia | 2.808E-04 | 1.148E-03 | PIK3CA, PIK3CB, TP53 |
| 09160 Human Diseases | 09161 Cancers | hsa05211 | Renal cell carcinoma | 2.083E-04 | 9.340E-04 | PIK3CA, PIK3CB, HIF1A |
| Unclassified | Unclassified | hsa01100 | Metabolic pathways | 1.110E-03 | 3.857E-03 | CYP2C9, PKM, MAOA, CYP1A2, PTGS2, CYP2C19, CYP3A4, PTGS1 |
| 09100 Metabolism | 09108 Metabolism of cofactors and vitamins | hsa00830 | Retinol metabolism | 1.991E-04 | 9.224E-04 | CYP2C9, CYP1A2, CYP3A4 |
| 09130 Environmental Information Processing | 09132 Signal transduction | hsa04012 | ErbB signaling pathway | 4.705E-04 | 1.817E-03 | PIK3CA, PIK3CB, EGFR |
| 09150 Organismal Systems | 09149 Aging | hsa04211 | Longevity regulating pathway - mammal | 5.901E-04 | 2.217E-03 | PIK3CA, PIK3CB, TP53 |
| 09130 Environmental Information Processing | 09132 Signal transduction | hsa04668 | TNF signaling pathway | 9.321E-04 | 3.322E-03 | PIK3CA, PIK3CB, PTGS2 |
| 09100 Metabolism | 09111 Xenobiotics biodegradation and metabolism | hsa00980 | Metabolism of xenobiotics by cytochrome P450 | 2.808E-04 | 1.148E-03 | CYP2C9, CYP1A2, CYP3A4 |
| 09150 Organismal Systems | 09151 Immune system | hsa04611 | Platelet activation | 1.257E-03 | 4.160E-03 | PIK3CA, PIK3CB, PTGS1 |
| 09150 Organismal Systems | 09156 Nervous system | hsa04722 | Neurotrophin signaling pathway | 1.198E-03 | 4.063E-03 | PIK3CA, PIK3CB, TP53 |
| 09160 Human Diseases | 09161 Cancers | hsa05206 | MicroRNAs in cancer | 1.736E-03 | 5.363E-03 | PIK3CA, PTGS2, TP53, EGFR |
| 09160 Human Diseases | 09167 Infectious diseases | hsa05162 | Measles | 1.717E-03 | 5.363E-03 | PIK3CA, PIK3CB, TP53 |
| 09130 Environmental Information Processing | 09132 Signal transduction | hsa04068 | FoxO signaling pathway | 1.611E-03 | 5.206E-03 | PIK3CA, PIK3CB, EGFR |
| 09160 Human Diseases | 09167 Infectious diseases | hsa05161 | Hepatitis B | 2.102E-03 | 6.130E-03 | PIK3CA, PIK3CB, TP53 |
| 09130 Environmental Information Processing | 09132 Signal transduction | hsa04072 | Phospholipase D signaling pathway | 2.021E-03 | 6.107E-03 | PIK3CA, PIK3CB, EGFR |
| 09130 Environmental Information Processing | 09132 Signal transduction | hsa04151 | PI3K-Akt signaling pathway | 2.865E-03 | 7.658E-03 | PIK3CA, PIK3CB, TP53, EGFR |
| 09130 Environmental Information Processing | 09132 Signal transduction | hsa04022 | cGMP-PKG signaling pathway | 3.076E-03 | 8.067E-03 | OPRD1, PIK3CA, PIK3CB |
| 09150 Organismal Systems | 09154 Digestive system | hsa04973 | Carbohydrate digestion and absorption | 2.810E-03 | 7.657E-03 | PIK3CA, PIK3CB |
| 09150 Organismal Systems | 09155 Excretory system | hsa04960 | Aldosterone-regulated sodium reabsorption | 2.117E-03 | 6.130E-03 | PIK3CA, PIK3CB |
| 09160 Human Diseases | 09161 Cancers | hsa05219 | Bladder cancer | 2.337E-03 | 6.498E-03 | TP53, EGFR |
| 09100 Metabolism | 09105 Amino acid metabolism | hsa00380 | Tryptophan metabolism | 2.226E-03 | 6.314E-03 | MAOA, CYP1A2 |
| 09150 Organismal Systems | 09155 Excretory system | hsa04964 | Proximal tubule bicarbonate reclamation | 7.355E-04 | 2.690E-03 | CA2, CA4 |
Human Diseases Associated with the Target Proteins of the Plant
Detailed Information of Human Diseases
| ICD10 Disease Category | Disease Name | ICD10 Code | Associated Disease Targets (Association Ref: TTD database) |
|---|---|---|---|
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Arthritis | M00-M25 | PTGS2; |
| S00-T88: Injury, poisoning and certain other consequences of external causes | Hyperthermia | T68 | PTGS2; |
| E00-E89: Endocrine, nutritional and metabolic diseases | Hyperlipidaemia | E78 | ESR1; |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Moderate to severe rheumatoid arthritis | M05-M06 | PTGS2; |
| N00-N99: Diseases of the genitourinary system | Female infertility due to anovulation | N97.0 | ESR1; |
| Q00-Q99: Congenital malformations, deformations and chromosomal abnormalities | Osteopetrosis | Q78.2 | ESR1; |
| Z00-Z99: Factors influencing health status and contact with health services | Oral contraceptive | Z30 | ESR1; |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Osteoarthritis | M15-M19, M47 | PTGS2; |
| C00-D49: Neoplasms | Late-stage solid tumors | C00-C75, C7A, C7B, D10-D36, D3A | PIK3CA; |
| C00-D49: Neoplasms | Leukemia | C90-C95 | ESR1; |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Knee osteoarthritis | M15-M19, M47 | PTGS2; |
| NA: NA | Postmenopausal disorder | NA | ESR1; |
| R00-R99: Symptoms, signs and abnormal clinical and laboratory findings, not elsewhere classified | Chronic pain | R52.1-R52.2, G89 | PTGS2; |
| NA: NA | Joint and muscular pain | NA | PTGS2; |
| N00-N99: Diseases of the genitourinary system | Irregularities | N92.6 | ESR1; |
| C00-D49: Neoplasms | Hormone refractory prostate cancer | C61 | ESR1; |
| G00-G99: Diseases of the nervous system G00-G99 | Pain | G64, G90.0, R52, G89 | ESR1; PTGS2; |
| C00-D49: Neoplasms | Pancreatic cancer | C25 | PTGS2; |
| C00-D49: Neoplasms | Clear cell renal cell carcinoma | C64 | CA9; |
| K00-K95: Diseases of the digestive system | Inflammatory bowel disease | K50, K51 | PTGS2; |
| E00-E89: Endocrine, nutritional and metabolic diseases | Inflammation | E08-E13, E10.2, E11, E11.2, E13.2, I73.9, I80-I82, N00-N29, G89 | PTGS2; |
| C00-D49: Neoplasms | Inflammatory disease | C11, C44, K75.9, M00-M25 | PTGS2; |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Female sexual dysfunction | F52 | ESR1; |
| N00-N99: Diseases of the genitourinary system | Female infertility | N97.0 | ESR1; |
| C00-D49: Neoplasms | Prostate cancer | C61 | ESR1; |
| H00-H59: Diseases of the eye and adnexa | Eye disorders | H00-H59 | ESR1; |
| E00-E89: Endocrine, nutritional and metabolic diseases | Hypogonadism | E23.0, E28.3, E29.1 | ESR1; |
| C00-D49: Neoplasms | Renal cancer | C64 | CA9; |
| I00-I99: Diseases of the circulatory system | Neurological disease | I21, I22, R52, R52.1-R52.2, R60.9, G89 | ESR1; |
| G00-G99: Diseases of the nervous system G00-G99 | Multiple scierosis | G35 | ESR1; |
| N00-N99: Diseases of the genitourinary system | Menopause symptoms | N95.0 | ESR1; |
| N00-N99: Diseases of the genitourinary system | Menorrhagia | N92.0 | ESR1; |
| N00-N99: Diseases of the genitourinary system | Infertility | N97.0 | ESR1; |
| C00-D49: Neoplasms | Non-small cell lung cancer | C33-C34 | PTGS2; |
| C00-D49: Neoplasms | Advanced prostate cancer | C61 | ESR1; |
| C00-D49: Neoplasms | Adrenocortical carcinoma | C74.0 | ESR1; |
| NA: NA | Rheumatold arthritis | NA | PTGS2; |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Rheumatoid arthritis | M05-M06 | PTGS2; |
| C00-D49: Neoplasms | Cancer | C00-C96 | ESR1; PIK3CA; PTGS2; PIK3CB; NQO2; CA9; |
| K00-K95: Diseases of the digestive system | Colon polyps | K63.5 | PTGS2; |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Osteoporosis | M80-M81, Z79.890 | ESR1; |
| L00-L99: Diseases of the skin and subcutaneous tissue | Acne vulgaris | L70.0 | ESR1; |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Ankylosing spondylitis | M08.1, M45 | PTGS2; |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Anxiety disorder | F32, F40-F42 | CYP3A4; |
| I00-I99: Diseases of the circulatory system | Thrombosis | I80-I82 | PIK3CB; |
| N00-N99: Diseases of the genitourinary system | Post-menopausal vaginal atrophy | N95.2 | ESR1; |
| G00-G99: Diseases of the nervous system G00-G99 | Neuropathic pain | G64, G90.0 | PTGS2; |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Gout | M10 | PTGS2; |
| G00-G99: Diseases of the nervous system G00-G99 | Alzheimer disease | G30 | PTGS2; |
| N00-N99: Diseases of the genitourinary system | Endometriosis | N80 | PTGS2; |
| N00-N99: Diseases of the genitourinary system | Vagina disease | N76.0 | ESR1; |
| C00-D49: Neoplasms | Solid tumours | C00-D48 | PIK3CA; PIK3CB; CA9; |
| N00-N99: Diseases of the genitourinary system | Dysmenorrhea | N94.4-N94.6 | ESR1; PTGS2; |
| N00-N99: Diseases of the genitourinary system | Dyspareunia | N94.1 | ESR1; |
| E00-E89: Endocrine, nutritional and metabolic diseases | Hormone deficiency | E00-E90 | ESR1; |
| E00-E89: Endocrine, nutritional and metabolic diseases | Estrogen deficiency | E28.39 | ESR1; |
| E00-E89: Endocrine, nutritional and metabolic diseases | Female hypogonadism | E23, E28 | ESR1; |
| E00-E89: Endocrine, nutritional and metabolic diseases | Autoimmune diabetes | E08-E13 | ESR1; |
| N00-N99: Diseases of the genitourinary system | Atrophic vaginitis | N95.2 | ESR1; |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Atrophy | M62.571 | ESR1; |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Arthralgia | M25.5 | ESR1; |
| J00-J99: Diseases of the respiratory system | Asthma | J45 | PTGS2; |
| C00-D49: Neoplasms | Brain cancer | C71, D33 | ESR1; |
| C00-D49: Neoplasms | Breast cancer | C50 | ESR1; NQO2; CA9; |
| NA: NA | Menopausal disorder | NA | ESR1; |
| Z00-Z99: Factors influencing health status and contact with health services | Contraception | Z30 | ESR1; |
| NA: NA | Gonorrheal vaginitis | NA | ESR1; |
| A00-B99: Certain infectious and parasitic diseases | Trematode infection | B66.9 | ESR1; |
| E00-E89: Endocrine, nutritional and metabolic diseases | Type 2 diabetes | E11 | PTGS2; |
| C00-D49: Neoplasms | Carcinoma | D00-D09 | ESR1; |
| Z00-Z99: Factors influencing health status and contact with health services | Hormone replacement therapy | Z79.890 | ESR1; |
| C00-D49: Neoplasms | Lymphoma | C81-C86 | CA9; |
>> Profiles of ingredients and activity landscape
>> Collective molecular activities profile at 10μM cutoff
>> Targets derived from weak experimental activities
